Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer cell Ročník 28; číslo 1; s. 11
Hlavní autoři: Kelderman, Sander, Schumacher, Ton N, Kvistborg, Pia
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 13.07.2015
Témata:
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
DNA Mismatch Repair
Humans
Neoplasms - drug therapy
Neoplasms - metabolism
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Tumor Microenvironment - drug effects
ISSN:1878-3686, 1878-3686
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of sensing the consequences of DNA damage in cancer immunotherapy.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccell.2015.06.012